Announcements Trials
Browse Landscape

Phase

Phase 1/2 9Phase 1 9Phase 3 6Phase 2 4

Status

Active not recruiting 3Completed 2Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Ipilimumab 3tremelimumab 1tilsotolimod 1spartalizumab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Diabetes Mellitus, Insulin-Dependent, 12 × Clear all
NCT07000149 2026-03-10

eVOLVE-RCC02

AstraZeneca

Phase 3 Active not recruiting
1,116 enrolled
Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT05751928 2025-07-08

NEO-MIMAJOR

Biocad

Phase 3 Active not recruiting
411 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT05732805 2025-02-27

OCTAVA

Biocad

Phase 3 Active not recruiting
270 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT03302234 2023-09-26

KEYNOTE-598

Merck Sharp & Dohme LLC

Phase 3 Completed
568 enrolled 20 charts
Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03084471 2022-12-22

STRONG

AstraZeneca

Phase 3 Completed
867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Idera Pharmaceuticals, Inc.

Phase 3 Terminated
481 enrolled 22 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡